Clinical Trial Update: BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies [Phase 1]

View source ↗

Summary

Phase 1 trial update reporting results for BGB-3111 (zanubrutinib) in combination with obinutuzumab in participants with B-cell lymphoid malignancies; study sta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoid Malignancies

Drugs mentioned

• Brukinsa (zanubrutinib) (zanubrutinib)
• Gazyva (obinutuzumab) (obinutuzumab)

Snippet

Sponsor: BeiGene | Conditions: B-cell Lymphoid Malignancies | Phase 1 | Status: COMPLETED | Results posted: 2021-11-03